Sign up to receive email notification of new issues

ForteBio Interactions Newsletter Biosensor photo

October 2009    VOLUME 2    ISSUE 3

WWW.FORTEBIO.COM

 

New 2:1 Heterogeneous Ligand Model
Now Available for Kinetic Analysis

Krista Witte Ph. D., Sr. Director of Chemistry and Consumables R&D
kwitte@fortebio.com

When performing kinetic analysis it is always preferable to engineer the molecular system to study as simple an interaction as possible. For most protein-protein or small molecule-protein interactions, this means assaying and analyzing an interaction where one molecule in solution binds to one molecule on the biosensor surface, i.e. a 1:1 interaction. In this type of interaction, the reaction can be represented as Equation 1 (where A is the analyte in solution and B is the ligand on the surface).

However, in some cases, the interaction to be studied cannot be reduced to a simple 1:1 interaction model. One such case relevant to label-free kinetics is where two ligand species bind in parallel to an analyte species. This type of interaction can now be fit with the new 2:1 Heterogeneous Ligand (HL) fitting model available in the Octet Data Analysis 6.1 software or later. The 2:1 HL interactions can be represented as Equation 2 (where B1 and B2 are two different ligands on the surface and A is the analyte in solution). This model assumes that the interactions are non-cooperative and that the analyte in solution is a single species.

The 2:1 HL model is appropriate for use in situations when it is known that the ligand is not homogeneous or fully active. A few examples of this include when a ligand preparation is known to have a small percentage of misfolded protein that will bind to the analyte or if the immobilization of the ligand onto the biosensor surface has altered the activity.

When using this model to fit kinetic data, two sets of kinetics parameters (kon, koff, KD) will be calculated. These two sets of parameters correspond to the two interactions occurring in Equation 2. The percentage of these two kinetic interactions in the total binding can be determined by looking at the ratio of the two calculated Rmax parameters (Rmax1 and Rmax2). The Rmax will reflect the amount that the interaction contributes to the overall signal at saturation, and thus the predominant interaction will have the largest Rmax.

To aid in determining the predominant interaction, the Data Analysis Software tabulates the kinetic parameters with kon1, koff1, KD1 coming from the interaction with the largest Rmax and kon2, koff2, KD2 coming from the interaction with the smaller Rmax.

In the example shown in Figure 1, the receptor immobilized onto the biosensor surface is known to contain impurities which also bind to the analyte. The 1:1 interaction model does not adequately describe this interaction. The 2:1 HL model fits to the experimental data and provides information on both the predominant interaction (the receptor binding to the analyte) as well as the minor interaction (the impurity binding to the analyte).

The addition of this 2:1 HL model provides even greater flexibility to the Octet platform and allows for a larger breadth of kinetic analysis to be performed.

Automating Octet RED384 on
Tecan’s Freedom EVO Robot

Sriram Kumaraswamy, Ph. D., Product Manager
skumaraswamy@fortebio.com

Drug discovery is a long and arduous process that requires screening through thousands to millions of compounds or biologicals to find lead candidates. Pharmaceutical and biotechnology companies looking for rapid, reliable and high throughput methods to screen through their libraries have found the Octet system to be ideal for their workflow.

Within the drug discovery and development process, Octet users find their workflow is faster, more efficient and cost-effective. Some applications that benefit from the use of our Octet systems include:

  • Protein expression monitoring
  • Clone selection and screening
  • Hybridoma screening
  • Epitope mapping, binning and cross-blocking
  • Off-rate screening for antibody ranking
  • Immunogenicity
  • Small molecule and fragment screening

The large numbers of samples to be screened and the assay workflow including the liquid handling steps can be automated on the Octet 384 systems. These systems have been designed to have an open architecture that enables integration with a variety of robotic systems.

With the Octet RED384 and the Octet QK384, the Octet platform offers two automation-capable systems that provide rapid results and complete walk-away for screening thousands of samples and binding interactions for the drug discovery researcher. To enable a turnkey robotic solution, ForteBio and Tecan have collaborated to automate our Octet 384 systems with the Freedom EVO robot.

At the recently concluded SBS ELRIG Meeting in Liverpool, UK, Tecan and ForteBio launched their integration showcasing automated label-free assays on the Octet. The EVO software is fully integrated with the Octet software. Tecan will provide custom hotels and carriers to enable movement of biosensor trays, sample and reagent containing microplates in and out of the Octet, thus enabling complete walk-away for experiments involving multiple microplates and biosensor trays.

 

^ TOP